doi: 10.1016/S1262-3636(16)30006-4
10.1210/endocr/bqad153 [DOI] [PMC free article] [PubMed] [Google Scholar] Mao T., Zhang C., Yang S., Bi Y., Li M., Yu J
Options for Your Genetic Testing The Comprehensive Health Test This report provides an integrated overview of an individuals health, combining genetic insights with personalised recommendations
Switching between Rybelsus formulations Do not switch between Rybelsus formulations during the initiation phase (Days 1-30) After 30 days, patients may switch between Rybelsus formulations using the following ratios: Formulation R1 7 mg and Formulation R2 4 mg may be switched for each other Formulation R1 14 mg and Formulation R2 9 mg may be switched for each other When switching between the formulations, initiate the other Rybelsus formulation the day after discontinuing the previous one Switching between Ozempic and Rybelsus Ozempic to Rybelsus formulation R1 One week after discontinuing 0.5 mg of subcutaneous Ozempic, start 7 mg or 14 mg of Rybelsus (formulation R1) orally once daily Switching recommendations for patients taking Ozempic 0.25 mg, 1 mg, or 2 mg subcutaneously once weekly to Rybelsus (formulation R1) are not available Ozempic to Rybelsus formulation R2 One week after discontinuing 0.5 mg of subcutaneous Ozempic, start 4 mg or 9 mg of Rybelsus (formulation R2) orally once daily Switching recommendations for patients taking Ozempic 0.25 mg, 1 mg, or 2 mg subcutaneously once weekly to Rybelsus (formulation R2) are not available Kidney disease No dose adjustment is necessary for any degree of renal impairment Liver disease No dose adjustment is necessary for any degree of hepatic impairment Other Do not split, crush, or chew tablets Leave tablets in blister pack until ready for use Generic / Price NO/$$$$ Soliqua Insulin glargine + lixisenatide Insulin glargine + lixisenatide Dosage forms Pen (100/33) 100 units/ml insulin glargine and 33 mcg/ml lixisenatide Pens contain 3 ml Comes in package of 5 pens Pen window shows units of insulin glargine Dosing Type 2 diabetes Insulin glargine is a long-acting insulin, and lixisenatide is a GLP-1 analog Pen is dialed to units of insulin glargine
The cardiovascular benefits appear to precede any significant weight management and apply to people with or without type 2 diabetes
